Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma
Integrin α5β1 was suggested to be involved in glioblastoma (GBM) aggressiveness and treatment resistance through preclinical studies and genomic analysis in patients. However, further protein expression data are still required to confirm this hypothesis. In the present study, we investigated by immu...
Main Authors: | Nelly Etienne-Selloum, Julien Prades, Diana Bello-Roufai, Mathieu Boone, Henri Sevestre, Stéphanie Trudel, Pascal Caillet, Alexandre Coutte, Christine Desenclos, Jean-Marc Constans, Sophie Martin, Laurence Choulier, Bruno Chauffert, Monique Dontenwill |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/9/882 |
Similar Items
-
Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin
by: Saidu Sani, et al.
Published: (2022-01-01) -
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy
by: Paccapelo Alessandro, et al.
Published: (2012-05-01) -
Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer
by: Elisabete Cruz da Silva, et al.
Published: (2019-05-01) -
Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps
by: Valeria Cuccarini, et al.
Published: (2024-04-01) -
Partial Sperm beta1 Integrin Subunit Deletion Proves Its Involvement in Mouse Gamete Adhesion/Fusion
by: Virginie Barraud-Lange, et al.
Published: (2020-11-01)